Canadian Co-infection Cohort- last updated: 25-03-2014

Publications and Presentations

Publications

  1. Cox J, Maurais E, Hu L, Moodie EEM, Law S, Bozinoff N, Potter M, Rollet K, Hull M, Tyndall M, Cooper C, Gill J, Saeed S, Klein MB. Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. Accepted in Drug & Alcohol Dependence 2014.
  2. Moodie EEM, Stephens DA, Klein MB. A marginal structural model for multiple-outcome survival data: assessing the impact of injection drug use on several causes of death in the Canadian Co-infection Cohort. Stat Med. 2013 Nov 25. doi: 10.1002/sim.6043.
  3. Schnitzer ME, Moodie EEM, van der Laan MJ, Platt RW, Klein MB. Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with Targeted Maximum Likelihood Estimation. Biometrics 2013 (in press)
  4. Young J, Potter M, Cox J, Cooper C, Gill J, Hull M, Walmsley S, Klein MB. Variation between Canadian centres in the uptake of treatment for Hepatitis C by patients co-infected with HIV. CMAJ Open 2013 (in press)
  5. Beauchamp E, Rollet K, Walmsley S, Wong DK, Cooper C, Klein MB; the Canadian Co-infection Cohort Study (CTN222). Missed opportunities for hepatocellular carcinoma screening in an HIV-Hepatitis C virus co-infected cohort. Clin Infect Dis. 2013 Jul 29. [Epub ahead of print]
  6. Brunet L, Moodie EEM, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB, and the Canadian Co-infection Cohort Investigators. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C co-infection: a longitudinal cohort analysis. Clin Infect Dis 2013. doi:10.1093/cid/cit378
  7. Klein MB, Rollet K, Saeed S, Cox J, Potter M for the Canadian Co-infection Cohort Study Investigators. HIV and hepatitis C virus co-infection in Canada: Challenges and opportunities for reducing preventable morbidity and mortality. HIV Med 2013; 14(1):10-20.
  8. Klein MB, Rollet K, Hull M, Cooper C, Walmsley S, Conway B, Pick N. Who needs direct acting antivirals for Hepatitis C Virus (HCV)? Challenges faced in advancing HCV therapy for HIV-HCV co-infected persons. Antivir Ther 2012; doi: 10.3851/IMP2484.
  9. Hull MW, Rollet K, Klein MB. Reply to Mandorfer et al. Clin Infect Dis. 2012 Dec 27.
  10. Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB. Insulin Resistance is associated with progression to hepatic fibrosis among a cohort of HIV/HCV co-infected patients. AIDS2012; 26(14):1789-94.
  11. Hull MW, Rollet K, Odueyungbo A,Saeed S, Potter M, Cox J, Cooper C, Gill J, Klein MB and the Canadian Co-infection Cohort Investigators. Factors associated with discordance between absolute CD4 cell count and CD4 percentage in HIV/Hepatitis C co-infected patients. Clin Infect Dis 2012; 54(12):1798-805.
  12. Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-Hepatitis C Virus Co-infection. AIDS 2011; 25(7):967-975.
  13. Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD. Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. AIDS 2010; 24(17):2639-44.
  14. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39(5):1162-9.
  15. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, Saeed S, Benko E, Kovacs C, Kaul R, Ostrowski MA. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010; 40(9):2493-505.
  16. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB for the Canadian Co-infection Cohort Study Investigators. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-co-infection before and after antiretroviral therapy. AIDS 2010; 24(12):1857-65.
  17. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009; 4(2):4517-21.
  18. Al-Morhi H, Murphy T, Lalonde RG, Klein MB. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. J Acquir Immune Defic Syndr 2007; 44:463-9.
  19. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a Simple Model for Predicting Liver Fibrosis in HIV/Hepatitis C (HCV) Co-infected Patients. HIV Medicine 2005; 6:375–378.

Abstracts and conference presentations

1.Rollet-Kurhajec KC, Tyndall M, Walmsley S, Cooper C, Conway B, Hull M, Cox J, Martel-Laferiere V, Rachlis A, Klein MB. The Impact of Smoking Tobacco and Other Drugs on Respiratory Illnesses among HIV/HCV Co-infected Patients. 23nd Annual Canadian Conference on HIV/AIDS Research, St John’s, NL, Canada, May 1-4, 2014.

2.Jenabian M-A, Kema I, Ramirez RP, Saeed S, Rollet K, Vyboh K, Tejada J-C, Gilmore N, Klein MB, Routy J-P. Viral control and immune activation in HIV HCV patients: Contribution of liver fibrosis and Tryptophan catabolism in ART-treated HIV/HCV infected patients. 23nd Annual Canadian Conference on HIV/AIDS Research, St John’s, NL, Canada, May 1-4, 2014.

3.Brunet L, Moodie EEM, Cox J, Pick N, Hull M, Conway B, Cooper C, Walmsley S, Tyndall M, Klein MB. Does Opioid Use Play a Role in Progression of Liver Fibrosis in HIV-Hepatitis C (HCV) Co-Infection? 23nd Annual Canadian Conference on HIV/AIDS Research, St John’s, NL, Canada, May 1-4, 2014 (Oral presentation).

4.Brunet L, Moodie EEM, Cooper C, Walmsley S, Martel-Laferrière V, Rollet K, Klein MB. Assessing the magnitude of bias due to exposure misclassification: an example of hazardous drinking and progression to fibrosis in the Canadian Co-infection Cohort Study.18th International Workshop on HIV Observational Databases, Sitges, Spain, March 2014.

5.Rossi C, Rollet K, Brunet L, Klein MB. Association between HCV RNA status and all-cause mortality in a cohort of HCV-HIV co-infected Canadians. 3rd Canadian Symposium on Hepatitis C Virus, Toronto, February 2014. (oral presentation)

6.Moqueet N, Kanagaratham C, Radzioch D, Saeed S, Klein MB. Differential Immune Marker Levels Linked to Liver Fibrosis in HIV/Hepatitis C (HCV) Co-infection. 21st Conference on Retroviruses and Opportunistic Infections, Boston, March 2014. Note: Recipient of young investigator award.

7.Rollet-Kurhajec KC, Gill J, Cooper C, Hull M, Cox J, Conway B, Pick N, Vachon M-L, Klein MB. Incidence Rates and Risk Factors for Severe Bacterial Infections in HIV/HCV Co-infected Patients. 21st Conference on Retroviruses and Opportunistic Infections, Boston, March 2014.

8.Moqueet N, Young J, Lisle C, Carter R, Klein MB for the Canadian Co-Infection Cohort (CTN222). Favourable IL28B Genotypes and Liver Fibrosis in HIV/Hepatitis C (HCV) Co-Infected Individuals from the Canadian Co-Infection Cohort. 2013 Canadian Society for Epidemiology and Biostatistics Biennial Conference, St. John’s, June 2013.

9.Moqueet N, Lisle C, Carter R, Platt R, Hull M, Cooper C, Walmsley S, Potter M, Klein MB for the Canadian Co-Infection Cohort (CTN222). Favourable IL28B Genotypes and Liver Fibrosis in HIV/Hepatitis C (HCV) Co-Infected Individuals from the Canadian Co-Infection Cohort. European Association for the Study of the Liver, Amsterdam, April 2013.

10.Yeung MW, Rollet K, Cooper C, Cox J, Hull M, Pick N, Rachlis A, Tyndall M, Walmsley S, Klein MB for the Canadian Co-Infection Cohort (CTN222). Overcoming hepatitis C: changes in quality of life, healthcare use, and substance use in HIV-coinfected patientsafter HCV therapy. 22nd Canadian Conference on HIV/AIDS Research, Vancouver, April 2013. (oral presentation)

11.Cox J, Maurais E, Moodie E, Walmsley S, Cooper C, Hull M, Pick N, Harris M, Conway B, Klein MB for the Canadian Co-Infection Cohort (CTN222). Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort (CTN222): improving the social determinants of health may help. 22nd Canadian Conference on HIV/AIDS Research, Vancouver, April 2013.

12.Klein MB, Moodie EEM, Stephens DA, Tyndall M, Walmsley S, Gill J, Cooper C for the Canadian Co-Infection Cohort (CTN222). Patterns of injection drug use and mortality in the Canadian HIV/HCV Co-infection Cohort. International Workshop on HIV Observational Databases, Cavtat, Croatia, April 2013.

13.Klein MB, Rollet K, Young J, Walmsley S, Rachlis A, Moodie EEM for the Canadian Co-Infection Cohort (CTN222). Liver fibrosis progression in HIV/Hepatitis C Virus Co-infection: Can immunosuppression before antiretroviral therapy be overcome? International Workshop on HIV Observational Databases, Cavtat, Croatia, April 2013. (oral presentation)

14.Brunet L, Moodie EEM, Cooper C, Hull M, Potter M, Walmsley S, Klein MB for the Canadian Co-Infection Cohort (CTN222). Prescribed and illicit opioid use in the Canadian HIV/HCV co-infection cohort and progression to liver disease. International Workshop on HIV Observational Databases, Cavtat, Croatia, April 2013.

15.Moqueet N, Young J, Lisle C, Carter R, Klein M for the Canadian Co-Infection Cohort (CTN222). Favourable IL28B genotypes are associated with Spontaneous Clearance but not aboriginal ancestry in Canadian HIV/HCV co-infected individuals from the Canadian Co-infected Cohort. Canadian Association for the Study of the Liver, Victoria, March 2013. (oral presentation)

16.Cooper C, Rollet K, Vasquez C, Potter M, Gill J, Pick N, Walmsley S, Tyndall M, Klein M for the Canadian Co-Infection Cohort (CTN222). HIV Virologic Rebounds but not Blips Predict Liver Fibrosis Progression in Antiretroviral Treated HIV-HCV Co-Infected Patients. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 2013.

17.Brunet L, Moodie E, Young J, Tyndall M, Hull M, Cooper C, Walmsley S, Gill J, Potter M, Klein M for the Canadian Co-Infection Cohort (CTN222). Marijuana Smoking and Progression to Liver Fibrosis, Cirrhosis and End-stage Liver Disease (ESLD) in HIV/HCV Co-infected Individuals. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 2013. Note: Recipient of young investigator award

18.Moqueet N, Young J, Lisle C, Carter R, Klein M for the Canadian Co-Infection Cohort (CTN222). Favourable IL28B genotypes are associated with Spontaneous Clearance but not aboriginal ancestry in Canadian HIV/HCV co-infected individuals. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 2013.

19.Melendez-Pena CE, Santamaria C, Conway B, Cooper C, Segatto B, Ward B, M Ndao, Klein M for the Canadian Co-Infection Cohort (CTN222). Proteomic Fingerprinting in HCV mono- and HIV-1/HCV Co-infection reveals plasma Biomarkers prognostic of fibrosis. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 2013. Note: Recipient of young investigator award

20.Rollet K, Moodie E, Pick N, Walmsley S, Cooper C, Cox J, Potter M, Gill J, Klein MB for the Canadian Co-Infection Cohort (CTN222). Female gender is associated with liver fibrosis progression in antiretroviral treated HIV-HCV co-infected patients. 3rd International Workshop on HIV & Women, Toronto, January 2013. (oral presentation)

21.Moqueet N, Young J, Klein MB for the Canadian Co-Infection Cohort (CTN222). IL28B and spontaneous clearance in HIV/HCV co-infected individuals from the Canadian Co-infection Cohort. Canadian Society for Epidemiology and Biostatistics National Student Conference, Saskatoon, May 2012. (oral presentation)

22.Brunet L, Moodie EE, Rollet K, Tyndall M, Potter M, Conway B, Walmsley S, Pick N, Cooper C, Cox J, Klein MB for the Canadian Co-Infection Cohort (CTN222). Marijuana smoking does not appear to cause progression of liver fibrosis in the Canadian HIV/HCV Co-infection Cohort Study. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012. (oral presentation) Note: Recipient of new investigator award

23.Klein MB, Rollet K, Saeed S, Cooper C, Conway B, Cox J, Gill J, Pick N, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222).Mortality in HIV-Hepatitis C virus (HCV) co-infected persons enrolled in the Canadian Co-infection Cohort study in comparison to the Canadian population. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012. (oral presentation)

24.Klein MB, Rollet K, Saeed S, Moodie E, Cox J, Cooper C, Gill J, Hull M, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222).Who needs direct acting antivirals for hepatitis C virus (HCV)? Challenges faced in advancing HCV therapy with direct acting antivirals (DAAs) in HIV-HCV co-infected persons. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012. (oral presentation)

25.Potter M, Young J, Rollet K, Cox J, Walmsley S, Cooper C, Tyndall M, Montaner J, Conway B, Pick N, CôtéP, Rouleau D, Klein MB for the Canadian Co-Infection Cohort (CTN222). Estimating variations between health care centres in the uptake of hepatitis C virus (HCV) treatment in HIV-HCV co-infected patients. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012. (oral presentation)

26.Melendez-Pena C, Habayeb M, Saeed S, Conway B, Cooper C, Ward B, Ndao M, Klein MB for the Canadian Co-Infection Cohort (CTN222). Serum biomarkers predictive of fibrosis by proteomic fingerprinting in HIV-1/HCV co-infection. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012. (oral presentation)

27.Maurais E, Cox J, Rollet K, Potter M, Pick N, Walmsley S, Moodie EE, Rouleau D, Klein MB for the Canadian Co-Infection Cohort (CTN222). Exploring perceived health by HIV-HCV co-infected persons. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012.

28.Brunet L, Moodie E, Rollet K, Tyndall M, Cooper C, Walmsley S, Pick N, Klein MB for the Canadian Co-infection Cohort (CTN222). Heroin use is associated with progression to cirrhosis in HIV-HCV coinfected patients. (Abstract O_O3) 7th International HIV and Hepatitis Co-infection Workshop, Milan, June 2011. (oral presentation)

29.Hull M, Yang H, Odueyuao A, Saeed S, Montaner J, Klein MB for the Canadian Co-infection Cohort Investigators (CTN222). Factors associated with discordance between absolute CD4 cell count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. International HIV and Hepatitis Co-infection Workshop, Milan, June 2011. (oral presentation)

30.Brunet L, Mofid L, Rollet K, Moodie E, Potter M, Cooper C, Klein MB for the Canadian Co-infection Cohort (CTN222). Tobacco and marijuana smoking and progression of liver fibrosis in HIV-HCV co-infected patients. 20th Canadian Conference on HIV/AIDS Research, Toronto, April 2011.

31.Odueyungbo A, Lemire B, Wong A, Sicard C, Mousseau K, Sheehan NL, Perreault S, Saeed S, Moodie E, Klein MB and the Canadian Co-Infection Cohort Study (CTN222).Use of propensity score matching to adjust for baselineimbalance in longitudinal HIV databases: Association betweenmale gender and progression of renal insufficiency among HIVpatients. 20th Canadian Conference on HIV/AIDS Research, Toronto, April 2011.

32.Beauchamp E, Rollet K, Tyndall M, Potter M, Cooper C, Klein MB.Hepatocellular carcinoma (HCC) screening in an HIV-HCV co-infected cohort. 20th Canadian Conference on HIV/AIDS Research, Toronto, April 2011.

33.Pick N, Rollet K, Burdge D, Fernandes E, Maan E, Saeed S, Klein MB, for the Canadian Co-infection Cohort (CTN222) Gender and Liver Disease Progression in HIV Hepatitis C Virus (HCV) Co-infection. 20th Canadian Conference on HIV/AIDS Research, Toronto, April 2011.

34.Odueyungbo A, Lemire B, Wong A, Sicard C, Mousseau K, Sheehan NL, Perreault S, Saeed S, Moodie E, Klein MB and the Canadian Co-Infection Cohort Study (CTN222). Use of propensity score matching to adjust for baseline imbalance in longitudinal HIV databases: Association between male gender and progression of renal insufficiency among HIV patients. 15th International Workshop on HIV Observational Databases, Prague, March 2011.

35.Habayeb M, Odueyungbo A, Rollet K, Saeed S, Walmsley S, Pick N, Conway B, Cox J, Hull M, Klein MB and the Canadian Co-infection Cohort Study (CTN222). LDL Level as Prognostic Tool for Liver Disease Progression in HIV-Hepatitis C Virus (HCV) Co-Infection. 18th Conference on Retroviruses and Opportunistic Infections, Boston, March 2011.

36.Lemire B, Wong A, Sicard C,Mousseau K,Odueyungbo A, Sheehan N,Perreault S, Saeed S, Klein MB and the Canadian Co-infection Cohort Study (CTN222). Hepatitis C Co-Infection Leads to Greater Loss of Renal Function in HIV-Infected Patients. 18th Conference on Retroviruses and Opportunistic Infections, Boston, March 2011.

37.Pick N, Castillo E, Rollet K, Burdge D, Saeed S, Klein MB, Canadian HIV-HCV Co-infection Cohort (CTN222). Gender and liver disease progression in HIV-hepatitis C co-infection. 1st International Workshop on HIV & Women, Washington DC, January 2011. (oral presentation)

38.Lemire B, Wong A, Sicard C,Mousseau K,Odueyungbo A, Sheehan N,Perreault S, Saeed S, Klein MB and the Canadian Co-infection Cohort Study (CTN222). La co-infection par l'hépatite C mène à une plus grande perte de fonction rénale chez les patients infectés par le VIH. La Journée des étudiants du FRSQ, Montreal, November 2010.

39.Potter M, Yang H, Saeed S, Cox J, Klein MB for the Canadian Co-infection Cohort (CTN222). Obstacles to hepatitis C virus (HCV) treatment among HIV-HCV co-infected persons in Canada. XVIII International AIDS Conference, Vienna, July 2010.

40.Cox J, Law S, Bozinoff N, Potter M, Odueyungbo A, Saeed S, Klein MB for the Canadian Co-infection Cohort Study (CTN222). Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort (CCC): a step towards improving HCV therapy access. XVIII International AIDS Conference, Vienna, July 2010.

41.Hull M, Yang H, Odueyungbo A, Saeed S, Montaner J, Klein MBfor the Canadian Co-infection Cohort Investigators (CTN222). Factors associated with discordance between absolute CD4 count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. 6th International HIV and Hepatitis Co-infection Workshop, Tel Aviv, Isreal, June 2010. (oral presentation)

42.Thorpe J, Saeed S, Moodie EE, Klein MB for the Canadian Co-infection Cohort Study (CTN222). Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in HIV/HCV Co-infected Adults. Oral Presentation. 19th Canadian Conference on HIV/AIDS Research, Saskatoon, May 2010.

43.Adams A, Rouleau D, Cox J, Saeed S, Klein MB for the Canadian Co-infection Cohort Study (CTN222). Poor quality of life in HIV-Hepatitis C Virus (HCV) Co-infection is predominately a consequence of unfavourable social conditions. 19th Canadian Conference on HIV/AIDS Research, Saskatoon, May 2010.

44.Klein MB, Thorpe J, Saeed S, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. A portrait of HIV-Hepatitis C co-infected persons in care in Canada: The Canadian Co-Infection Cohort Study (CTN222). 19th Canadian Conference on HIV/AIDS Research, Saskatoon, May 2010.

45.Thorpe J, Saeed S, Moodie EE, Klein MB for the Canadian Co-infection Cohort Study (CTN222). Interruption of Antiretroviral Therapy (ART) is Associated with Progression of Liver Fibrosis in HIV/HCV Co-infected Adults. 15th International Workshop on HIV Observational Databases, Barcelona, March 2010.

46.Moodie EE, Saeed S, Rouleau D, Cox J, Klein MB for the Canadian Co-infection Cohort Study (CTN222). Extending Marginal Structural Models for Competing Risks: The Effect ART Interruptions on Death. 15th International Workshop on HIV Observational Databases, Barcelona, March 2010.

47.Thorpe J, Saeed S, Moodie EE, Klein MB for the Canadian Co-Infection Cohort Study (CTN222). Interruption of Antiretroviral Therapy (ART) is associated with progression of liver fibrosis in HIV/HCV co-infected adults. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. Note: Recipient of new investigator award

48.Potter M, Yang H, Saeed S, Klein MB for the Canadian Co-Infection Cohort Study (CTN222). Successful Hepatitis C Virus (HCV) Treatment Improves CD4-T lymphocyte Reconstitution in HIV/HCV Co-infected Adults. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. Note: Recipient of new investigator award

49.Fregonese F, Yang H, Saeed S, Klein MB for the Canadian Co-Infection Cohort Study (CTN222). Predictors of end stage liver disease (ESLD) in patients with HIV and HCV co-infection. 18th Canadian Conference on HIV/AIDS Research, Vancouver, April 2009.